Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$40.32 USD

40.32
2,751,724

+0.06 (0.15%)

Updated Aug 12, 2024 04:00 PM ET

After-Market: $40.34 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is Celgene (CELG) Poised for a Beat This Earnings Season?

Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.

    Is Gilead (GILD) Poised for a Beat This Earnings Season?

    A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.

      Swarup Gupta headshot

      Foreign Stock Roundup SAP, Taiwan Semiconductor Earnings Impress, Ericsson Disappoints

      Heightened geopolitical concerns, emanating from the Catalonia crisis and stalled Brexit negotiations weighed on Europe's stocks last week.

        Novartis Reports Positive Results on Thrombocytopenia Drug

        Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.

          FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx

          Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.

            Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

            GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

              Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit

              Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.

                Emergent Completes Acquisition of Anthrax Drug Raxibacumab

                Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.

                  Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg

                  Mylan N.V. (MYL) gets a boost with the FDA's approval of the generic version of multiple sclerosis drug Copaxone.

                    Advanced Accelerator (AAAP) Cancer Therapy Approved in EU

                    Advanced Accelerator Applications' (AAAP) Lutathera gets approval in Europe as its first radionuclide therapy for the treatment of tumors in the gut.

                      Agenus (AGEN) Remains Focused on Drug Development Programs

                      Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.

                        AstraZeneca's Bevespi Improves Lung Function in Phase III Study

                        AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.

                          J&J's Arthritis Candidate Sirukumab Denied FDA Approval

                          J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.

                            Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III

                            GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.

                              How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry

                              GlaxoSmithKline (GSK) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

                                Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?

                                GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                                  Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD

                                  The FDA approves GlaxoSmithKline (GSK) and Innoviva's triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market.

                                    Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU

                                    Glaxo's (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.

                                      Glaxo's Shingles Candidate Gets Positive FDA Committee Vote

                                      Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.

                                        Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise

                                        Amgen (AMGN) and AstraZeneca (AZN) announced promising data from a phase IIb study on tezepelumab, which reduced the rate of deterioration of asthma in patients with severe uncontrolled asthma.

                                          Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018

                                          Novartis AG (NVS) announced that its Chief Executive Officer (CEO), Joseph Jimenez will step down from his position in 2018.

                                            Arpita Dutt headshot

                                            Key FDA Regulatory Events to Watch Out for in Sep 2017

                                            Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan's biosimilars?

                                              Mylan and Otsuka Ink Agreement to Commercialize Deltyba

                                              Mylan (MYL) and Otsuka Pharmaceutical have entered into a license agreement to commercialize Deltyba in developing countries.

                                                Why Have Mylan's (MYL) Shares Lost 19.4% So Far This Year?

                                                Shares of Mylan N.V. (MYL) have lost almost 19.4% in the year so far given the competitive pressure.

                                                  Are Glaxo's Successful New Drugs Enough to Drive Growth?

                                                  Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked.